Institute for Wealth Management LLC. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 808 shares of the biopharmaceutical company’s stock, valued at approximately $393,000.

A number of other institutional investors and hedge funds have also modified their holdings of REGN. Alpha Windward LLC boosted its stake in Regeneron Pharmaceuticals by 0.3% in the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 1 shares in the last quarter. Cleararc Capital Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 0.3% during the first quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock worth $717,000 after purchasing an additional 5 shares during the last quarter. Regentatlantic Capital LLC increased its stake in shares of Regeneron Pharmaceuticals by 0.9% in the second quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 5 shares in the last quarter. Capital Planning Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 2.1% in the second quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 12 shares in the last quarter. Finally, Sequoia Financial Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.7% in the second quarter. Sequoia Financial Advisors LLC now owns 712 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 12 shares in the last quarter. Hedge funds and other institutional investors own 67.95% of the company’s stock.

In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 189 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the sale, the chief financial officer now directly owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Sanofi purchased 166,415 shares of the firm’s stock in a transaction on Thursday, August 24th. The stock was bought at an average cost of $480.93 per share, with a total value of $80,033,965.95. The disclosure for this purchase can be found here. Insiders sold a total of 85,968 shares of company stock valued at $40,699,948 in the last quarter. 10.80% of the stock is currently owned by company insiders.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded up 2.93% on Monday, reaching $460.24. 315,435 shares of the company’s stock were exchanged. The stock has a market cap of $48.80 billion, a P/E ratio of 46.17 and a beta of 1.63. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $543.55. The company’s 50 day moving average price is $468.97 and its 200-day moving average price is $447.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.82 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.93 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Institute for Wealth Management LLC. Acquires Shares of 808 Regeneron Pharmaceuticals, Inc. (REGN)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/10/02/institute-for-wealth-management-llc-acquires-shares-of-808-regeneron-pharmaceuticals-inc-regn.html.

A number of research analysts recently issued reports on the company. Leerink Swann reaffirmed a “positive” rating and issued a $552.00 price target (down from $580.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Piper Jaffray Companies reiterated an “overweight” rating and set a $557.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 1st. Robert W. Baird reissued a “sell” rating and set a $408.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, September 8th. Evercore ISI started coverage on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 16th. They set an “outperform” rating and a $605.00 price objective on the stock. Finally, Barclays PLC restated an “equal weight” rating and issued a $450.00 price objective (up previously from $400.00) on shares of Regeneron Pharmaceuticals in a research report on Saturday, July 22nd. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $489.35.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.